Healthcare Movers: Intercept Pharmaceuticals Inc. (NASDAQ:ICPT), Pernix Therapeutics (NASDAQ:PTX), Galena Biopharma (NASDAQ:GALE), Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

FB Nasdaq FB Facebook

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) is lower after the company reported mixed Q4 and full-year 2013 earnings, as well as releasing results for its Phase 3 POISE trial. Shares are now down 10.71% at $412.75, but are still at the higher end of its 52-week range of $30.38 – $497.00 On Friday, Intercept (NASDAQ:ICPT) reported a loss per share of $0.64, compared to a loss of $2.02 for the same quarter the previous year and better than analyst expectations of a loss of $0.70 per share, if comparable. Revenue for the quarter was flat at $405 million.

Separately, the company disclosed Sunday positive results for its Phase 3 POISE trial of obeticholic acid (OCA) for the treatment of primary biliary cirrhosis (PBC), noting it met the primary endpoint with high statistical significance. Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) also reported that generally mild to moderate pruritus, or itching, was observed as the most frequently reported adverse event associated with OCA treatment.

Pernix Therapeutics (NASDAQ:PTX) is firmer after the company reported mixed financial results for Q4, missing on EPS, but beating on revenue. Shares are up 4.87% at $3.66, with a 52-week range of $1.68 – $6.35. The specialty pharmaceutical company reported a Q4 net loss of $5.6 million, or $0.15 per diluted share, compared with the prior-year period’s net loss of $1.4 million, or $0.05 per diluted share.

Pernix Therapeutics (NASDAQ:PTX)’s revenue was $23.9 million, up 31% from $18.2 million in the same quarter last year. Analysts polled by Capital IQ were expecting a loss per share of $0.08 on revenues of $21.70 million.

Galena Biopharma (NASDAQ:GALE) shares were up 6.7% pre-market Monday as the biotech company prepared to report its Q4 results after the closing bell.

Galena Biopharma (GALE) was trading near $3.37 in a 52-week range of $1.65 to $7.77. Analysts expect a loss of $0.09 and revenue of $1.62 million, according to Capital IQ.

Analysts at RBC Capital Markets have raised their price target on ADRs of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) to $46 from $39 a share. The firm left its sector perform rating on the stock unchanged.

In pre-market trading, shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) are up 0.76% to $49.25, amid a 52-week spread of $36.26 – $51.41.

 

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone